We believe in transparent science. Here is the peer-reviewed evidence that guides our clinical practice at Thai Wisdom Center.
Our Approach
Thai traditional medicine is a 2,500-year-old living system — and modern science is increasingly confirming the mechanisms behind practices that practitioners have observed empirically for generations. At Thai Wisdom Center, we integrate peer-reviewed pharmacological and clinical research into every treatment decision, while honouring the holistic foundations of our tradition.
Study 01 · Receptor Pharmacology
Kruegel, A.C. et al. (2016). Journal of Medicinal Chemistry, 59(15), 7011–7028.
This landmark study characterised mitragynine — the principal alkaloid of Mitragyna speciosa (Kratom, กระท่อม), a plant used in traditional Thai medicine for pain management and fatigue — as a partial agonist at the μ-opioid receptor (MOR). Using radioligand binding and functional assays, Kruegel and colleagues demonstrated that mitragynine displays measurable MOR affinity while showing a pharmacological profile distinct from classical full opioid agonists.
Crucially, the study revealed that mitragynine also acts as an antagonist or partial agonist at δ- and κ-opioid receptors, which may contribute to a different side-effect profile compared to conventional opioid analgesics. The authors proposed that this biased agonism profile could underpin the analgesic effects observed in traditional use while potentially reducing respiratory depression risk — a hypothesis that has catalysed significant follow-up research.
This receptor-level understanding informs how our practitioners approach pain management consultations, particularly for patients seeking alternatives to pharmaceutical analgesics. Our prescribing is guided by evidence of MOR partial agonism and individual patient assessment.
This was primarily an in vitro pharmacological characterisation study. Clinical translation requires further human trials. TWC does not extrapolate binding data directly to clinical dosing without clinical evidence support.
Study 02 · Safety Profile
Prozialeck, W.C. et al. (2012). Journal of the American Osteopathic Association, 112(12), 792–799.
Prozialeck's review examined population-level use patterns and adverse-event reports for Mitragyna speciosa, contextualising the safety profile relative to commonly used analgesics including NSAIDs and opioids. The analysis found that at traditional Thai dosage levels — small amounts consumed as a tea — reported adverse events were generally mild and self-limiting, in contrast to the gastrointestinal, renal and cardiovascular risks associated with chronic NSAID use.
The study highlighted the importance of dose, preparation method and individual variation. It also noted that the great majority of adverse-event reports in Western contexts involved concentrated extracts or co-ingestion with other substances — patterns distinct from traditional Thai use. The authors called for controlled clinical studies to formally establish dose–response relationships and long-term safety parameters.
Study 03 · Thai Clinical Research
Faculty of Traditional Thai Medicine, Prince of Songkla University, Songkhla, Thailand. Ongoing research series.
Thailand's Prince of Songkla University (PSU) hosts one of the most comprehensive ongoing research programmes focused on the pharmacognosy and clinical applications of Mitragyna speciosa within its traditional Thai medical context. This multi-year project involves alkaloid profiling of regional plant specimens, controlled animal studies examining analgesic and anti-inflammatory mechanisms, and observational data collection from traditional users in Southern Thailand.
Importantly, the PSU programme distinguishes between traditional aqueous preparations (leaf decoctions consumed in small volumes) and the concentrated commercial extracts that dominate the Western market. Their phytochemical analyses have identified over 40 alkaloids in Thai specimens, with mitragynine comprising 60–66% of total alkaloid content in leaves — providing the pharmacognostic basis for standardised clinical dosing.
Thai Wisdom Center maintains an advisory relationship with PSU's research faculty. Our herb farm contributes standardised plant specimens to ongoing phytochemical studies, and our clinical team participates in observational data-sharing initiatives.
Following Thailand's 2021 decriminalisation of Mitragyna speciosa, the plant is now legally cultivated, processed and used within the traditional Thai medicine framework. TWC operates in full compliance with Thailand's FDA regulations for traditional herbal medicines.
Study 04 · Neurochemistry
Matsumoto, K. et al. (2004). Life Sciences, 74(24), 2997–3006.
Matsumoto and colleagues conducted a series of neurochemical antagonism studies in rodent models to delineate the descending pain-modulation pathways through which mitragynine exerts its antinociceptive effects. Using selective α₂-adrenoceptor and 5-HT₂A receptor antagonists, the team demonstrated that mitragynine's analgesic activity is substantially mediated through both the noradrenergic and serotonergic systems — in addition to (and partly independent of) opioid receptor activation.
This multimodal mechanism may explain why traditional Thai medicine practitioners have long observed analgesic and mood-modulating effects that do not align neatly with classic opioid pharmacology. The engagement of spinal and supraspinal monoaminergic pathways places mitragynine in a pharmacologically distinct category with a mechanism comparable in some respects to serotonin–noradrenaline reuptake inhibitors used in neuropathic pain management.
Study 05 · Comprehensive Review
Kruegel, A.C. & Grundmann, O. (2018). Neuropharmacology, 134(Pt A), 108–120.
This comprehensive review synthesised the state of knowledge regarding kratom's alkaloid chemistry, receptor pharmacology, clinical observations and regulatory landscape as of 2018. Kruegel and Grundmann systematically mapped the binding profiles of the major alkaloids — mitragynine, 7-hydroxymitragynine, corynantheidine, speciociliatine and others — against opioid, adrenergic and serotonergic receptors, presenting the most integrated picture of kratom neuropharmacology available at that time.
The authors concluded that the pharmacological profile of the alkaloid mixture is genuinely novel — neither a classic opioid nor a purely monoaminergic agent — and called for dedicated Phase II clinical trials to characterise therapeutic windows and safety parameters in human subjects. This remains the most-cited review in the field and is a cornerstone reference for TWC's clinical decision-making framework.
Our Own Research
We are not content to simply cite the work of others. Thai Wisdom Center operates an active clinical research programme designed to generate real-world outcome data from our patient cohorts.
We are conducting a longitudinal outcomes study tracking pain scores, quality-of-life measures and medication use in patients completing our 30- and 90-day resident wellness programmes. Data collection began January 2025 with an initial target cohort of 120 participants.
In collaboration with PSU, we are building a phytochemical reference database for the 80+ medicinal plant species cultivated on our GMP farm, documenting seasonal alkaloid variation, standardisation protocols and quality benchmarks.
Our clinical team documents and de-identifies complex patient cases for publication in Thai and international traditional medicine journals. Two case series manuscripts are currently under peer review (chronic musculoskeletal pain; post-COVID fatigue syndromes).
Patients enrolling in our 30-day and 90-day programmes are invited to participate in our observational outcomes study. Participation is entirely voluntary and involves completing standardised questionnaires at intake, mid-programme and 90-day post-discharge. All data are anonymised and managed in accordance with Thailand's Personal Data Protection Act (PDPA). Enquire at the time of booking if you wish to participate.
Frequently Asked Questions
A growing body of peer-reviewed research supports the pharmacological activity of key Thai medicinal plants. Studies published in journals including the Journal of Medicinal Chemistry and Neuropharmacology have characterised receptor-level mechanisms. TWC integrates this evidence into clinical practice while acknowledging areas where further clinical trial data are still needed.
Safety depends on the specific herbs and pharmaceuticals involved. Our licensed doctors are trained in herb–drug interaction assessment. All patients are screened for current medications before any herbal prescription is issued. Certain combinations require caution and our doctors will advise each patient accordingly during consultation.
Thai herbal medicinal products are regulated by the Thai Food and Drug Administration (FDA) under the Traditional Thai Medicine Act. Products produced at our GMP-certified facility comply with all FDA requirements and are appropriately classified for OTC or prescription use.
Yes. Our ongoing clinical research programme includes observational outcome studies, case series and phytochemical database work. We collaborate with Thai universities including Prince of Songkla University and aim to publish findings in peer-reviewed journals.
We prioritise peer-reviewed articles published in indexed journals, systematic reviews and research from recognised academic institutions. We clearly acknowledge the limitations of each study and distinguish between preclinical and clinical evidence throughout this page.
Consult with our licensed practitioners and see how evidence-based Thai medicine can support your health goals.
Book a Consultation